Join us for a virtual Analyst and Investor R&D Event with ProQR Therapeutics, where the Company will showcase its proprietary Axiomer® RNA-editing technology platform, announce initial pipeline targets for internal development, and provide guidance on the advancement of programs toward the clinic. Speakers from the Company will include Daniel A. de Boer, Founder and CEO, Gerard Platenburg, Chief Scientific Officer, and René Beukema, Chief Corporate Development Officer.

The event will also feature a presentation by Peter Beal, PhD (University of California at Davis) who will discuss the opportunity available for ProQR’s Axiomer® technology to yield a new class of medicines for both rare and prevalent diseases with unmet need.

In addition, the Company plans to issue its full year 2022 operating and financial results on March 29.

A live Analyst question and answer session will follow the formal presentations.